Advanced Minimal Residual Disease Detection Using a Novel Circulating Tumor DNA Assay: A Report of Two Cases.

ABSTRACT:

Introduction

Tumor-informed minimal residual disease (MRD) monitoring assays based on plasma circulating tumor DNA (ctDNA) are increasingly integrated into the clinical management of patients with cancer. In the post-surgical curative intent setting and as an adjunct to radiographic imaging for response assessment and surveillance, timely identification of MRD may better guide therapeutic decision-making. The increasing clinical adoption of MRD testing, supported by a growing body of evidence demonstrating its potential utility at critical decision points across diverse tumor histology, has brought attention to the variability in the analytical performance of available ctDNA assays. This variability is becoming increasingly appreciated as a key factor influencing clinical performan

SUBMITTER: Azzi G 

PROVIDER: S-EPMC12503468 | biostudies-literature | 2025 Jan-Dec

REPOSITORIES: biostudies-literature